Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Neurofibromatosis type 2 (NF2) is a schwannoma predisposition syndrome, alongside schwannomatosis related to germline LZTR1 and SMARCB1 pathogenic variants.
|
31425178 |
2019 |
Neurilemmoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These data, together with the expression of SMARCB1 protein in a proportion of cells from schwannomatosis-related schwannomas, suggest that these tumors develop through a mechanism that is distinct from that of rhabdoid tumors in which SMARCB1 protein is completely absent in tumor cells.
|
22949514 |
2012 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Previously, we demonstrated that the SMARCB1 exon 2 missense mutation c.143 C > T segregates with the presence of meningiomas in five members of a large family with multiple meningiomas and schwannomas.
|
22038540 |
2012 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A novel germline SMARCB1 mutation was found in one patient; inactivating somatic mutations of NF2, associated with loss of heterozygosity (LOH) of 22q, were found in two schwannomas of this patient.
|
18072270 |
2008 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline SMARCB1 mutations predispose in schwannomatosis patients to the development of multiple benign schwannomas and, in some cases, meningiomas.
|
24525513 |
2014 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
SMARCB1 mutations predispose to rhabdoid tumors and schwannomas but the mechanisms underlying the tumor type specificity are unknown.
|
28824165 |
2017 |
Neurilemmoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The present data suggests that (a) mosaic loss of immunohistochemical INI1/SMARCB1 expression, despite the interlesional variability, is a reliable marker of schwannomatosis regardless of the involved gene and it might help in the differential diagnosis of schwannomatosis vs. solitary schwannomas and (b) INI1/SMARCB1 expression is not useful in the differential with mosaic NF2, since NF2-associated peripheral schwannomas show the same immunohistochemical pattern.
|
28365909 |
2017 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1.
|
19124645 |
2009 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.
|
24362817 |
2014 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
An unusual case of schwannomatosis with bilateral maxillary sinus schwannomas and a novel SMARCB1 gene mutation.
|
26431068 |
2016 |
Neurilemmoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining with a SMARCB1 antibody revealed a mosaic SMARCB1 expression pattern in the three benign schwannomas, but absence of expression in the malignant tumor cells of the pRCC1.
|
26799435 |
2016 |
Neurilemmoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings support the hypothesis that SMARCB1 is a tumor suppressor for schwannomas in the context of familial disease.
|
18647326 |
2008 |
Neurilemmoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
|
22614000 |
2012 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among those with peripheral tumors, the median tumor number was 4 in the LZTR1 group (median total body tumor volume 30 cc) and 10 in the SMARCB1 group (median volume 85cc), (P=.2915 for tumor number and P = .2289 for volume). mutation was associated with an increased prevalence of spinal schwannomas (100% vs 41%, P = .0197).
|
29384852 |
2018 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We therefore directly sequenced seven SMARCB1 exons (90% of the open reading frame) in search for mutations in 41 meningiomas and 23 schwannomas.
|
10208879 |
1999 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
By immunohistochemistry, both the epithelioid malignant peripheral nerve sheath tumor and the schwannomas showed a complete loss of the Smarcb1 protein.
|
22082606 |
2012 |
Neurilemmoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Although the exact oncogenetic mechanism in these schwannomas remains to be elucidated, our findings suggest that INI1 is the predisposing gene in familial schwannomatosis.
|
17357086 |
2007 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemistry with a SMARCB1 antibody revealed a mosaic staining pattern in schwannomas of the patients with the c.30delC and c.34C>T mutations.
|
24740647 |
2014 |
Neurilemmoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
A few schwannomas and malignant peripheral nerve sheath tumors showed mosaic or complete loss of SMARCB1 expression.
|
26520417 |
2016 |
Neurilemmoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, SMARCB1-associated schwannomas follow a four-hit, three-step model, in which both alleles of SMARCB1 and NF2 genes are inactivated in the tumor, with one of the steps being always the loss of a big part of chromosome 22 involving both loci.
|
25739810 |
2015 |
Neurilemmoma
|
0.200 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that patients with schwannomas have a significant probability of carrying a SMARCB1 mutation.
|
21255467 |
2011 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This finding demonstrates that a SMARCB1 mutation may be the initial "hit" (constitutional) for a genetic disorder with subsequent risk of developing schwannomas and other malignancies, and raises the possibility that other patients with switch/sucrose non-fermenting (SWI/SNF) mutations may be at increased risk for tumors.
|
26364901 |
2015 |
Neurilemmoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We describe a patient with multiple schwannomas and mutation in the recently described INI1 gene, which also predisposes to the disease.
|
20854059 |
2011 |
Neurilemmoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Germline SMARCB1 mutations have recently been identified as a pathogenic cause of a subset of familial schwannomatosis cases, and SMARCB1 is a candidate gene for causation of both schwannomas and meningiomas.
|
20472658 |
2010 |